IIT Bombay-incubated startup ImmunoACT announced that it has received Central Drugs Standard Control Organisation's approval for India's first CAR-T cell therapy. The Laurus Labs-backed company's therapy, called NexCAR19, is designed to treat certain types of blood cancer like leukemia. As per reports, Indians willing to avail this therapy till now mostly went to US where it cost over ₹3.3 crore.